Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hemostemix Inc (TSV: HEM ) 0.0800 -0.0050 (-5.88%) Streaming Delayed Price Updated: 3:22 PM EST, Nov 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 9,000 Open 0.0900 Bid (Size) 0.0850 (70) Ask (Size) 0.1000 (800) Prev. Close 0.0850 Today's Range 0.0800 - 0.0900 52wk Range 0.0350 - 0.1100 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board September 27, 2022 Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board September 20, 2022 Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... Via Newsfile Performance YTD +14.29% +14.29% 1 Month +23.08% +23.08% 3 Month +77.78% +77.78% 6 Month +100.00% +100.00% 1 Year +9.59% +9.59% More News Read More Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board September 16, 2022 Via Newsfile Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board September 15, 2022 Via Newsfile Topics Intellectual Property Exposures Intellectual Property Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board September 14, 2022 Via Newsfile Hemostemix Announces Its Presentation to the Emerging Growth Conference September 14, 2022 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc. September 13, 2022 Via Newsfile Hemostemix Announces Closing of $2,750,000 April 26, 2022 Via IssueWire Topics Intellectual Property Exposures Intellectual Property Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed April 13, 2022 Via IssueWire Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years September 14, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results July 06, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Peter Lacey Increases His Investment in Hemostemix Inc. June 21, 2021 Via Newsfile Topics Intellectual Property Exposures Intellectual Property Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture June 11, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix to Present at the Emerging Growth Conference May 25, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property CEO Presenting on the Emerging Growth Conference on May 26 May 24, 2021 Via EIN Presswire Topics Cannabis LGBTQ Exposures Cannabis Diversity Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list April 23, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd. April 08, 2021 Via Newsfile Topics Economy Intellectual Property Exposures COVID-19 Economy Intellectual Property Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
